Close Menu


Which Tyrosine Kinase Inhibitor we must Apply before?: A Case Report of Crizotinib-Resistant Patient with Concomitant EGFR and EML4-ALK Gene Mutations

EGFR and ALK mutations are seen simultaneously very rarely. We believe that EGFR-TKI can be used to EGFR (except exon 20 insertions or T790M mutation) and ALK dual mutant patients as the first treatment. Examination of ROS1 mutation must be used as an indicator in the chose of the crizotinib treatment. Also, we believe that combined use of EGFR-TKI and ALK-TKI would at least increase the chance of success in patients with dual mutant.


The concomitant epidermal growth factor receptor  (EGFR) mutation and anaplastic lymphoma kinase (ALK) translocations in lung adenocancers are a very rare scenario. Until now, forty two cases described in the literature have all been treated by different drugs. There is no overall consensus regarding the treatment for this adenocarcinoma subgroup.

25 May, 2016
PDF Attachment: 
Journal Sections: 
e-Published: 06 Jul, 2016


Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.

Subscribe to RSS - Adenocancer
Top of Page